Abatacept And Infliximab Improve Clinical Response Over Time In Methotrexate-Refractory RA Patients

Results from the ATTEST TrialNew data presented at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France, show that over half of rheumatoid arthritis patients resistant to methotrexate monotherapy improved when either abatacept or infliximab were added to their methotrexate treatment regimen, with positive results sustained up to one year later.

More: continued here

Filed under: Arthritis on June 17th, 2008